X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
oncology (100) 100
female (90) 90
middle aged (87) 87
aged (86) 86
adult (79) 79
chemotherapy (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
index medicus (50) 50
treatment outcome (41) 41
breast cancer (40) 40
cancer (40) 40
male (38) 38
breast neoplasms - drug therapy (37) 37
paclitaxel (33) 33
prognosis (32) 32
aged, 80 and over (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
survival (26) 26
breast neoplasms - pathology (25) 25
carcinoma (25) 25
disease-free survival (25) 25
human (24) 24
article (23) 23
paclitaxel - administration & dosage (23) 23
trial (23) 23
epirubicin (22) 22
therapy (21) 21
priority journal (20) 20
antineoplastic combined chemotherapy protocols (19) 19
research (19) 19
survival analysis (19) 19
metastasis (18) 18
cancer survival (17) 17
carboplatin (17) 17
cisplatin (17) 17
clinical trial (17) 17
drug administration schedule (17) 17
medicine (17) 17
research article (17) 17
breast neoplasms - mortality (16) 16
neoplasm staging (16) 16
antineoplastic agents (15) 15
breast neoplasms (15) 15
carboplatin - administration & dosage (15) 15
care and treatment (15) 15
clinical trials (15) 15
doxorubicin (15) 15
major clinical study (15) 15
medicine & public health (15) 15
melanoma (15) 15
neoplasm metastasis (15) 15
young adult (15) 15
cyclophosphamide (14) 14
immunohistochemistry (14) 14
melanoma - drug therapy (14) 14
retrospective studies (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
chemotherapy, adjuvant (13) 13
drug therapy (13) 13
fluorouracil (13) 13
neutropenia (13) 13
advanced cancer (12) 12
analysis (12) 12
anemia (12) 12
antineoplastic agents - therapeutic use (12) 12
fluorouracil - administration & dosage (12) 12
gene expression (12) 12
phase-ii (12) 12
survival rate (12) 12
tumors (12) 12
controlled study (11) 11
greece (11) 11
hematology, oncology and palliative medicine (11) 11
patients (11) 11
protein expression (11) 11
thrombocytopenia (11) 11
adjuvant chemotherapy (10) 10
alopecia (10) 10
anthracyclines (10) 10
antimitotic agents (10) 10
biomarkers (10) 10
cancer patients (10) 10
diarrhea (10) 10
disease progression (10) 10
epirubicin - administration & dosage (10) 10
genetic aspects (10) 10
health aspects (10) 10
hospitals (10) 10
medical research (10) 10
neoplasms (10) 10
receptor, erbb-2 - metabolism (10) 10
recombinant granulocyte colony stimulating factor (10) 10
biomarkers, tumor - metabolism (9) 9
breast neoplasms - genetics (9) 9
breast neoplasms - metabolism (9) 9
colorectal cancer (9) 9
docetaxel (9) 9
drug efficacy (9) 9
erbb-2 protein (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, pp. 49 - 49
Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis... 
PI3K gene mutations | Biomarkers | EGFR ligands | BRAF | KRAS | Cetuximab | Epidermal growth factor receptor | 1ST-LINE TREATMENT | LEUCOVORIN | EPIREGULIN | STATISTICS | FLUOROURACIL | CHEMOTHERAPY | BREAST-CANCER | PANITUMUMAB | MUTATION STATUS | ONCOLOGY | Colorectal Neoplasms - genetics | Humans | Middle Aged | Glycoproteins - metabolism | Male | Antineoplastic Agents - therapeutic use | Epiregulin | Amphiregulin | RNA, Messenger - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | EGF Family of Proteins | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Colorectal Neoplasms - metabolism | Genes, ras - genetics | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Epidermal Growth Factor - metabolism | Genotype | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phosphatidylinositol 3-Kinase - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - secondary | Aged | Drugs | Adverse and side effects | Research | Drug therapy | Patient outcomes | Colorectal cancer | Medical research | Care and treatment | Genes | Metastasis | Antineoplastic agents | Formaldehyde | Antimitotic agents | Messenger RNA | Epidermal growth factor | Codon | Gene mutations | Analysis | Monoclonal antibodies | Medicine, Experimental | Genetic aspects | Biological markers | Health aspects
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0207707
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2012, Volume 7, Issue 6, p. e37946
Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in... 
PHASE-III TRIAL | COOPERATIVE ONCOLOGY GROUP | NEOADJUVANT CHEMOTHERAPY | MULTIDISCIPLINARY SCIENCES | PROTEIN EXPRESSION | TISSUE MICROARRAYS | BRAIN METASTASES | RISK | DENSE SEQUENTIAL CHEMOTHERAPY | PROGNOSTIC VALUE | DOCETAXEL | Immunohistochemistry | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Methotrexate - therapeutic use | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Cyclophosphamide - therapeutic use | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Young Adult | Disease-Free Survival | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Epirubicin - therapeutic use | Keratin-5 - metabolism | Adult | Female | Aged | Anthracyclines - therapeutic use | Medical research | Anthracyclines | Estrogen | Adjuvant treatment | Breast cancer | Metastasis | Keratin | Paclitaxel | Medicine, Experimental | Rankings | Progesterone | Health aspects | Cancer | Enrichment | Brain | Cytokeratin | Laboratories | Liver | Estrogens | Clinical trials | Estrogen receptors | Oncology | Nervous system | Paraffin | Cancer therapies | Subgroups | Metastases | Proteins | Cell growth | Mastectomy | Epirubicin | Drug dosages | Risk groups | Epidermal growth factor receptors | Health risks | Patients | Survival | ErbB-2 protein | Medicine | Studies | Pathology | Chemotherapy | Brain research | Hospitals | Anthracycline | Collaboration | Medical prognosis | Biomarkers | Trastuzumab | Tumors
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2010, Volume 8, Issue 1, pp. 3 - 3
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Journal Article